At a glance
(thousands of €, if not stated otherwise) |
Third quarter of 2020 |
Third quarter of 2019 |
Nine months ended 30 September 2020 |
Nine months ended 30 September 2019 |
Full year 2019 |
||
|---|---|---|---|---|---|---|---|
Income Statement |
|
|
|
|
|
||
Revenues |
131,816 |
633,934 |
333,589 |
725,719 |
844,985 |
||
Other income |
12,201 |
10,020 |
35,003 |
26,744 |
50,905 |
||
R&D expenditure |
(132,257) |
(120,680) |
(398,135) |
(298,247) |
(427,320) |
||
S, G&A expenses |
(44,115) |
(32,643) |
(133,612) |
(61,195) |
(98,278) |
||
Operating expenses |
(176,372) |
(153,323) |
(531,746) |
(359,442) |
(525,597) |
||
Operating profit/loss (–) |
(32,355) |
490,631 |
(163,154) |
393,021 |
370,292 |
||
Net financial results |
(49,163) |
(146,226) |
(83,297) |
(144,391) |
(220,233) |
||
Taxes |
(387) |
16,828 |
(1,096) |
16,699 |
(214) |
||
Net profit/loss (–) |
(81,905) |
361,233 |
(247,548) |
265,329 |
149,845 |
||
Balance Sheet |
|
|
|
|
|
||
Cash and cash equivalents |
2,087,797 |
5,599,787 |
2,087,797 |
5,599,787 |
1,861,616 |
||
Current financial investments |
3,220,805 |
– |
3,220,805 |
– |
3,919,216 |
||
R&D incentives receivables |
122,878 |
99,711 |
122,878 |
99,711 |
115,356 |
||
Assets |
5,721,086 |
5,851,752 |
5,721,086 |
5,851,752 |
6,068,609 |
||
Shareholders’ equity |
2,712,082 |
2,535,281 |
2,712,082 |
2,535,281 |
2,875,658 |
||
Deferred income |
2,789,183 |
3,127,777 |
2,789,183 |
3,127,777 |
3,000,646 |
||
Other liabilities |
219,821 |
188,695 |
219,821 |
188,695 |
192,305 |
||
Cash Flow |
|
|
|
|
|
||
Operational cash flow/ |
(202,784) |
3,454,585 |
(433,270) |
3,302,041 |
3,162,804 |
||
Cash flow used (–)/ |
(180,340) |
3,470,495 |
(390,169) |
3,328,758 |
3,208,617 |
||
Cash flow generated/used (–) in investing activities |
(81,084) |
(14,221) |
631,720 |
(22,881) |
(3,764,660) |
||
Cash flow generated in financing activities |
353 |
965,072 |
20,599 |
970,733 |
1,335,751 |
||
Increase/decrease (–) in cash and cash equivalents |
(261,073) |
4,421,347 |
262,149 |
4,276,610 |
779,708 |
||
Transfer to current financial investments |
– |
– |
– |
– |
(198,922) |
||
Effect of exchange rate differences on cash and cash equivalents |
(35,351) |
30,514 |
(35,968) |
32,380 |
(9,966) |
||
Cash and cash equivalents at end of the period |
2,087,797 |
5,599,787 |
2,087,797 |
5,599,787 |
1,861,616 |
||
|
|
|
|
|
|
||
Current financial investments at end of the period |
3,220,805 |
– |
3,220,805 |
– |
3,919,216 |
||
Total current financial investments and cash and cash equivalents at end of the period |
5,308,602 |
5,599,787 |
5,308,602 |
5,599,787 |
5,780,832 |
||
Financial Ratios |
|
|
|
|
|
||
Number of shares issued at end of the period |
65,340,842 |
61,953,831 |
65,340,842 |
61,953,831 |
64,666,802 |
||
Basic income/loss (–) per share (in €) |
(1.25) |
6.26 |
(3.81) |
4.77 |
2.60 |
||
Diluted income/loss (–) per share (in €) |
(1.25) |
6.03 |
(3.81) |
4.59 |
2.49 |
||
Share price at end of the period (in €) |
121.20 |
139.80 |
121.20 |
139.80 |
186.50 |
||
Total group employees at end of the period (number) |
1,407 |
918 |
1,407 |
918 |
1,003 |
||
|
|||||||
Employees per site as of 30 September 2020
(total: 1,407 employees)
